Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.

Core Insights - Lantern Pharma presented clinical data for LP-284 at the 25th Annual Lymphoma, Leukemia & Myeloma Congress, showcasing a complete metabolic response in a patient with aggressive DLBCL who had previously failed multiple therapies [1][3][4] - The drug LP-284 demonstrates potential as both a monotherapy and a combination therapy, addressing a significant market need in post-immunotherapy settings for patients with relapsed or refractory B-cell cancers [2][5][6] Clinical Data Presentation - A 41-year-old patient with Grade 3 DLBCL achieved a complete metabolic response after two cycles of LP-284, administered intravenously [2][4] - The patient had extensive bony lesions and had previously failed treatments including CAR-T and bispecific antibody therapies [2][4] Mechanism of Action - LP-284 operates through a novel synthetic lethal mechanism targeting DNA repair deficiencies, which allows it to be effective regardless of TP53 mutation status [4][11] - The drug has shown preclinical synergy with FDA-approved therapies, particularly with rituximab, enhancing its potential for combination treatments [4][9][11] Market Opportunity - DLBCL is the most common aggressive non-Hodgkin's lymphoma subtype, with around 200,000 new cases diagnosed globally each year, highlighting the critical need for effective treatments in this area [6][7] - LP-284 targets a market estimated at $3-4 billion annually for relapsed/refractory B-cell cancers, addressing both clinical and economic burdens [4][7] Development and Partnerships - Lantern Pharma is actively engaging with biopharmaceutical companies for potential partnerships, focusing on LP-284's use in combination regimens with existing therapies [9][14] - The ongoing Phase 1a study continues to evaluate LP-284's safety and efficacy, with favorable early results indicating a well-tolerated profile [8][12] Strategic Positioning - The company has received multiple FDA Orphan Drug Designations for LP-284, providing regulatory advantages and commercial exclusivity [11][15] - Lantern's RADR® AI platform is instrumental in accelerating drug development and identifying synergistic opportunities, enhancing the overall efficiency of the process [11][17]